Pharvaris Announces Pricing of Upsized Initial Public Offering

ZUG, Switzerland, Feb. 04, 2021 (GLOBE NEWSWIRE) — Pharvaris N.V. (“Pharvaris”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of
innovative therapies, including novel, small molecule bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications,
today announced